Modulation of SLFN11 induces changes in DNA Damage response

Abstract excerpt

<h4>Background:</h4> Lack of Schlafen family member 11 (SLFN11) expression has been recently identified as a dominant genomic determinant of response to DNA damaging agents in numerous cancer types. Thus, strategies aimed at increasing SLFN11 could be used to restore chemosensitivity of refractory cancers. As oncogenic downregulation is often driven by methylation of the promotor region, we explore the demethylat...

Topics

Open a Topic to create a Post that cites this publication.

• Cancer therapeutics and mechanisms
• CAR-T cell therapy research
• CRISPR and Genetic Engineering
• Cytokine Signaling Pathways and Interactions
• DNA Repair Mechanisms
• interferon and immune responses
• PARP inhibition in cancer therapy
• RNA Research and Splicing

Identifiers and source

Literature Corpus work

4d97282a-1595-56eb-ac47-bf2858187393

DOI

10.1101/2023.04.02.535254